Cohorts
The roots of HEDIMED emerge from the comprehensive data and sample resources generated in the large prospective birth and pregnancy cohorts, clinical trials and cross-sectional series. HEDIMED combines cohorts from countries with a high and low prevalence of immune-mediated diseases which facilitates the identification of both risk factors and protective factors.
As immune-mediated diseases start at a very young age, it is essential to study the disease progress in this early period. Therefore, these birth and pregnancy cohorts provide a unique position to identify factors contributing to the development of the immune-mediated disease.
The data and study endpoints of different cohorts are harmonised, new data is generated and novel research tools are developed for the analyses of exposomic disease determinants. Causality is studied using cell and organoid models and clinical trials with standardised exposomic interventions.
The pink and green bars indicate the relative frequencies of selected immune-mediated diseases in Finland and the Karelian Republic of Russia, respectively. As clearly shown, in Finland the frequency of atopic dermatitis, thyroid disease, celiac disease and type 1 diabetes is dramatically higher, regardless of the similar genetic background of these populations. This reflects the effect of completely different exposomal exposure and living environment of these two populations. Reference.
The HEDIMED project has access to the largest and most comprehensive set of data on immune-mediated diseases through its clinical cohorts.
These cohorts include prospective birth and pregnancy cohorts as well as clinical trials and cross-sectional cohorts. HEDIMED combines cohorts from countries with high and low prevalence for immune-mediated diseases which facilitates the studying of both risk factors and protective factors.
As immune-mediated diseases start at a very young age, it is essential to understand the disease progress in this early period. HEDIMED has access to multiple birth and pregnancy cohorts, which provides a unique position to study the development of the immune-mediated disease. HEDIMED also aims to elucidate the role of gender in disease incidence since gender seems to be an important factor in the pathogenesis of immune-mediated diseases.
The cohorts in HEDIMED are harmonised and study end-points specifically characterised. During the project, new data and samples are created and added to the dataset and new tools are developed to analyse this complex data. Causality is studied using cell and organoid models and clinical trials with standardised exposomic interventions.
| Countries with a high incidence of immune mediated diseases |
 |
Countries with a low incidence of immune mediated diseases |
 |
Cohorts that have both high and low incidence countries |
 |
|---|
| Countries with a high incidence of immune mediated diseases | Countries with a low incidence of immune mediated diseases | Cohorts that have both high and low incidence countries |
|---|---|---|
|
|
|
|
| Cohort | Country | Disease End Point | Cohort website |
|---|---|---|---|
|
CiPiS |
Sweden |
Celiac disease |
|
|
CiPP trial |
Sweden |
Celiac disease |
|
|
COPSAC |
Denmark |
Asthma, allergies |
|
|
DIPP |
Finland |
Type 1 diabetes, celiac disease, allergies, asthma |
|
|
DiPiS |
Sweden |
Type 1 diabetes |
|
|
MIDIA |
Norway |
Type 1 diabetes, celiac disease |
|
|
MoBa |
Norway |
Type 1 diabetes, celiac disease, asthma |
|
|
PREVALL trial Finland |
Finland |
Allergies |
|
|
PreCiSe trial |
Sweden |
Celiac disease |
|
|
FinKarelia |
Russian Karelia |
Type 1 diabetes, celiac disease, allergies |
|
|
GDME Tartu pregnancy cohort |
Estonia |
Type 1 diabetes |
|
|
HESEINT |
Italy |
Asthma |
|
|
PREVALL trial Estonia |
Estonia |
Allergies |
|
|
Diabimmune |
Finland, Estonia, Russian Karelia |
Type 1 diabetes, celiac disease, allergies |
|
|
HESE |
Italy, France, Sweden, Denmark, Norway |
Asthma |
|
|
SINPHONIE |
23 European countries |
Asthma |
|
|
VirDiab |
Finland, Sweden, Estonia, Lithuania, United Kingdom, France, Greece |
Type 1 diabetes |
|